ABBV (AbbVie Inc.) חוב לטווח קצר להון

AbbVie Inc. is expanding its portfolio through M&A transactions and partnerships with biotech laboratories to combat oncology. Changes in the short-term debt-to-equity ratio demonstrate financial stability, with the metric holding at 0.00. High costs for sterile logistics of biologics are offset by the successful market launch of new products, which stabilize the holding's overall profits.

This indicator determines the share of short-term liabilities within the equity structure to assess the risk of liquidity loss. By analyzing the historical share of short-term loans in the equity of AbbVie Inc. (ABBV), an investor can observe the balance between operational flexibility and debt load. For this biopharmaceutical behemoth, such funds are frequently allocated toward the environmental modernization of plants and the reduction of emissions. A stable trend confirms the financial resilience of the asset during the implementation of its sustainable development strategy.